Jan Öhrström
Chairman presso ONWARD MEDICAL N.V.
Profilo
Jan K.
Öhrström is currently the Chairman at Blaze Bioscience, Inc., Chairman at Onward Medical SA, Chairman at VarmX BV, Chairman at Onward Medical NV, Director at Polyganics BV, and President at Sitkabv.
Previously, he served as the Chief Executive Officer at ProFibrix BV from 2011 to 2014, Executive Chairman at Biom'Up SA in 2019, and Director at Avigen, Inc. He also held positions at Novo Nordisk A and Novo Nordisk Pharmaceutical Industries, Inc. as Director-Strategic Marketing and Medical Director respectively from 1990 to 1999.
Additionally, he was the Senior Vice President-Business Development at ZymoGenetics, Inc. from 2000 to 2007.
Dr. Öhrström obtained his doctorate degree from the University of Copenhagen in 1984.
Posizioni attive di Jan Öhrström
| Società | Posizione | Inizio |
|---|---|---|
| ONWARD MEDICAL N.V. | Chairman | 19/04/2016 |
Blaze Bioscience, Inc.
 Blaze Bioscience, Inc. Medical/Nursing ServicesHealth Services Blaze Bioscience, Inc. develops tumor paint products and Optide-based guided therapeutics for cancer patients. The firm provides BLZ-100. The company was founded by James M. Olson in 2010 and is headquartered in Seattle, WA. | Chairman | 01/04/2015 |
Polyganics BV
 Polyganics BV Medical SpecialtiesHealth Technology Polyganics BV engages in the development, manufacture, and commercialization of bioresorbable medical devices that facilitate tissue repair and regeneration. It offers pipeline, peripheral nerve repair, neurosurgery, and general surgery products . The company was founded in 1999 and is headquartered in Groningen, the Netherlands. | Director/Board Member | - |
Onward Medical SA
 Onward Medical SA BiotechnologyHealth Technology ONWARD Inc develops medical devices. It also provides stimulation system to rehabilitate individuals with spinal cord injury. The company was founded by Jocelyn Bloch, Sjaak Deckers, Grégoire Courtine, and Vincent Delattre in December 2014 and is headquartered in Lausanne, Switzerland. | Chairman | - |
| Sitkabv | President | - |
Varmx BV
 Varmx BV BiotechnologyHealth Technology VarmX BV is a spin-off from Leiden University Medical Center (LUMC) founded in 2016 by Professor Pieter Reitsma, a world-leading expert in hemostasis and thrombosis. VarmX is based in Leiden, NL. The Dutch company's lead compound, VMX-C001, is a modified recombinant blood factor X developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The company is supported by a strong syndicate of investors. Jan K. Öhrström has been the CEO of the company since 2018. | Chairman | 01/11/2018 |
Precedenti posizioni note di Jan Öhrström
| Società | Posizione | Fine |
|---|---|---|
| BIOM'UP | Chairman | 31/12/2019 |
ZymoGenetics, Inc.
 ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology ZymoGenetics, Inc. develops protein based drugs. It focuses on the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases, including homeostasis, inflammatory and autoimmune diseases, cancer, and viral infections. The company was founded by Earl W. Davie, Benjamin D. Hall and Michael Smith in 1981 and is headquartered in Seattle, WA. | Corporate Officer/Principal | 01/07/2007 |
| NOVO NORDISK A/S | Sales & Marketing | 01/01/1999 |
| ░░░░ ░░░░░░░ ░░░░░░░░░░░░░░ ░░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░ ░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | - |
Formazione di Jan Öhrström
| University of Copenhagen | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| NOVO NORDISK A/S | Health Technology |
| ONWARD MEDICAL N.V. | Commercial Services |
| Aziende private | 10 |
|---|---|
Avigen, Inc.
 Avigen, Inc. Medical SpecialtiesHealth Technology Avigen, Inc. produces and sells drugs, animal health products, and chemicals. The firm also develops and commercializes small molecules of therapeutics and biologics for use in the treatment of serious neurological and neuromuscular disorders. The company was founded in 1992 and is headquartered in La Jolla, CA. | Health Technology |
ZymoGenetics, Inc.
ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology ZymoGenetics, Inc. develops protein based drugs. It focuses on the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases, including homeostasis, inflammatory and autoimmune diseases, cancer, and viral infections. The company was founded by Earl W. Davie, Benjamin D. Hall and Michael Smith in 1981 and is headquartered in Seattle, WA. | Health Technology |
Blaze Bioscience, Inc.
Blaze Bioscience, Inc. Medical/Nursing ServicesHealth Services Blaze Bioscience, Inc. develops tumor paint products and Optide-based guided therapeutics for cancer patients. The firm provides BLZ-100. The company was founded by James M. Olson in 2010 and is headquartered in Seattle, WA. | Health Services |
Novo Nordisk Pharmaceutical Industries, Inc.
 Novo Nordisk Pharmaceutical Industries, Inc. Pharmaceuticals: MajorHealth Technology Part of Novo Nordisk A/S, Novo Nordisk Pharmaceutical Industries, Inc. is a private company that manufactures pharmaceutical preparations. The company is based in Clayton, NC. | Health Technology |
Polyganics BV
Polyganics BV Medical SpecialtiesHealth Technology Polyganics BV engages in the development, manufacture, and commercialization of bioresorbable medical devices that facilitate tissue repair and regeneration. It offers pipeline, peripheral nerve repair, neurosurgery, and general surgery products . The company was founded in 1999 and is headquartered in Groningen, the Netherlands. | Health Technology |
ProFibrix BV
 ProFibrix BV BiotechnologyHealth Technology ProFibrix BV develops and markets products for the hemostasis and regenerative medicine markets. Its product in pipeline, ProFibrix, is a hemostatic agent for mild to moderate surgical bleeding. The firm operates through its offices located in Leiden and Seattle. It is a subsidiary of The Medicines Company. The company was founded in 2004 by Jaap Koopman and is headquartered in Leiden, the Netherlands. | Health Technology |
Biom'Up SA
 Biom'Up SA Medical SpecialtiesHealth Technology Biom'Up SA engages in the development of hemostatic product composed of patent-protected biopolymers. Its products include Hemoblast Bellows and Hemosnow. The company was founded by Patricia Forest, Sylvain Picot and Christian Gagnieu on February 21, 2005 and is headquartered in Lyon, France. | Health Technology |
Onward Medical SA
Onward Medical SA BiotechnologyHealth Technology ONWARD Inc develops medical devices. It also provides stimulation system to rehabilitate individuals with spinal cord injury. The company was founded by Jocelyn Bloch, Sjaak Deckers, Grégoire Courtine, and Vincent Delattre in December 2014 and is headquartered in Lausanne, Switzerland. | Health Technology |
Varmx BV
Varmx BV BiotechnologyHealth Technology VarmX BV is a spin-off from Leiden University Medical Center (LUMC) founded in 2016 by Professor Pieter Reitsma, a world-leading expert in hemostasis and thrombosis. VarmX is based in Leiden, NL. The Dutch company's lead compound, VMX-C001, is a modified recombinant blood factor X developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The company is supported by a strong syndicate of investors. Jan K. Öhrström has been the CEO of the company since 2018. | Health Technology |
| Sitkabv |
- Borsa valori
- Insiders
- Jan Öhrström
